Becton, Dickinson and Company (BDX)
Curious about Becton Dickinson (BDX) Q3 Performance? Explore Wall Street Estimates for Key Metrics
Evaluate the expected performance of Becton Dickinson (BDX) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Earnings Preview: Becton Dickinson (BDX) Q3 Earnings Expected to Decline
Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Becton Dickinson gets its spinoff deal, but the stock is still falling
Becton Dickinson will spin off its biosciences and diagnostic business and merge it with Waters, and plans to use at least $2 billion of the proceeds to buy back stock.
3 Undervalued Dividend King Stocks With Over 50% Upside Potential
As we enter the second half of 2025, now is the perfect time to invest in dividend stocks — especially those with quality underlying fundamentals that pay high dividend yields.
Becton, Dickinson and Company (BDX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)
Becton, Dickinson and Company (NYSE:BDX ) Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 2:00 PM ET Company Participants Thomas E. Polen - President, CEO & Chairman Conference Call Participants Robert Justin Marcus - JPMorgan Chase & Co, Research Division Unidentified Analyst Yes.
Becton, Dickinson: A Dividend King Facing Challenges Offers Value
Becton, Dickinson is significantly undervalued, trading at 12.3x earnings with a 2.5% dividend yield, the highest in a decade. The company boasts a 53-year streak of dividend growth, excellent dividend safety, and a conservative payout ratio, making it a reliable Dividend King. Despite tariff headwinds, competition, and restructuring risks, BDX's innovation, acquisitions, and organic growth support long-term revenue and EPS expansion.
BD Stock Might See Short-term Decline After Warning on Tamponade Tubes
BDX warns of safety risks tied to its esophagogastric balloon tamponade tubes after one death and two injuries, prompting updated usage instructions for clinicians.
BD Stock May Rise Following the Launch of FACSDiscover A8 Platform
BDX unveils the BD FACSDiscover A8, a next-gen cell analyzer with spectral flow cytometry and real-time imaging, enabling deeper insights into cell function and biology.
Becton, Dickinson and Company (BDX) Bank of America Securities Health Care Conference - (Transcript)
Becton, Dickinson and Company (NYSE:BDX ) Bank of America Securities Health Care Conference Call May 13, 2025 1:00 PM ET Company Participants Tom Polen - Chairman, Chief Executive Officer and President Conference Call Participants Travis Steed - Bank of America Securities Travis Steed [Starts Abruptly] I'm Travis Steed, Medical Device Analyst at Bank of America and I'm fortunate to have Tom Polen up next, CEO at Becton, Dickinson. So welcome.
9 Dividend Aristocrats Potentially Set To Soar, No Matter What Happens Next
I'm going on a 2-week vacation with my family for my sister's wedding, so I've prepared a comprehensive article with three types of dividend aristocrat recommendations for whateveriscomingnext. Low-volatility aristocrats offer a 3.4% yield, a 46% downside capture ratio, and 52% less volatility than the S&P, making them ideal for addressing recession concerns while still providing a 23% return. High-yield aristocrats offer a 7% average yield with 11%-12% long-term return potential, providing low-risk income regardless of market or economic conditions.
Medical-products maker Becton Dickinson says cuts in global research funding have hurt sales
Becton Dickinson & Co.'s stock fell more than 15% on Thursday toward its worst one-day loss in 26 years after the medical-products maker said global cuts in research funding are impacting its research instrument sales.
William Blair downgrades Becton Dickinson on 'disappointing' Q2 update
01 May
